Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas (Q37788239)

23 August 2017

title

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas (English)

1 reference

23 August 2017

1

Fatih M Uckun

1 reference

23 August 2017

Sanjive Qazi

2

1 reference

23 August 2017

publication date

1 September 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1407-1418

1 reference

Structure and function of Syk protein-tyrosine kinase

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Syk tyrosine kinase required for mouse viability and B-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Transmembrane signaling by antigen receptors of B and T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Tyrosine kinase activation in the decision between growth, differentiation, and death responses initiated from the B cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Syk-dependent and -independent signaling cascades in B cells elicited by osmotic and oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

The microtubule-associated protein tau is phosphorylated by Syk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Structure of tubulin at 6.5 A and location of the taxol-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Therapeutic prospect of Syk inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Therapeutic nanoparticles for drug delivery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Treatment of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Childhood acute lymphoblastic leukaemia and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Mar

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Bone-marrow relapse in paediatric acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Proteomic and genetic approaches identify Syk as an AML target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

Syk Is Required for p38 Activation and G2/M Arrest in B Cells Exposed to Oxidative Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.112

21 January 2018

Identifiers

DOI

10.1586/ERA.10.112

1 reference

23 August 2017

1 reference